Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors

By Lim Joline S. J.   Tan David S. P.  

Cancers, Vol. 9, Iss. 8, 2017-08 ,pp. : 109-109

MDPI

Access to resources Recommend Favorite

PARP Inhibitors in Ovarian Cancer

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 13, Iss. 4, 2018-11 ,pp. : 392-410

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors

By Belani Chandra P.  

Cancer Investigation, Vol. 28, Iss. 4, 2010-04 ,pp. : 413-423

Informa Healthcare

Access to resources Recommend Favorite

Marine Metabolites Overcoming or Circumventing Multidrug Resistance Mediated by ATP-Dependent Transporters: A New Hope for Patient with Tumors Resistant to Conventional Chemotherapy

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 8, Iss. 8, 2008-12 ,pp. : 886-903

Bentham Science Publishers

Access to resources Recommend Favorite

“Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?

By Margariti Nadia  

Breast Cancer Research and Treatment, Vol. 128, Iss. 3, 2011-08 ,pp. : 599-606

Springer Publishing Company

Access to resources Recommend Favorite